You should consider shares of Credit Suisse Group AG (NYSE:CS) and Aldeyra Therapeutics Inc. (NASDAQ:ALDX) if you are looking for a great stocks to invest in. Starting with the CS shares, which traded at $12.83 at the close of the recent session, dropping -2.14%. On Tuesday, the company’s shares shed -$0.28 from its value which represented in intraday trading. The stock is now 8.54% higher in year-to-date (YTD) trading. CS’s intraday high was $12.84 while its lowest price touched $12.74. The stock’s 52-week high price is $13.62, which means the current price is at -5.80%. In terms of trading activity, the daily trading volume rose to 2772290 against 200-day average trading volume of 2,562,730 shares.
What are analyst forecasts for Credit Suisse Group AG (NYSE:CS)?
At a consensus rating of 3.50, CS is trending as a streaking Moderate Buy, as it has been the case a month ago when 8 analysts called it a Hold. Two months ago, 8 analysts recommended, on average, that CS stock is a Hold. The Financial company’s shares’ overall bearish trend saw it close higher on Tuesday compared to its opening price of $12.82 on the day.
Forecasts for Credit Suisse Group AG (NYSE:CS) give the stock a fair value for the growth of 11.7% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $14.53, which means the price per share could rise by nearly $1.7. The price range target is between a low of $12.03 and a high of $18.29. The stock would need to gain by about $29.85 to hit the estimated high or 0.8% from its 12-month low.
The consensus among 19 analysts is that it is a good time for one to Overweight in the Credit Suisse Group AG. 7 analysts rate CS as a Buy, with 1 of 19 analysts rate it as a Sell. 3 have valued the stock as Overweight and 8 have recommended that investors Hold.
Credit Suisse Group AG (NYSE:CS) Upgrades and Downgrades
In terms of rating changes, Exane BNP Paribas on August 30, 2019, Upgrade Credit Suisse Group AG (CS) at Outperform. Analysts at JP Morgan have assigned a Neutral rating for the stock in their research note on March 13, 2019. Moreover, Keefe Bruyette analysts issued a rating of Underperform for the stock on March 12, 2019. On February 20, 2019, the stock earned a Hold rating due to an analyst call from Berenberg, while analysts from Morgan Stanley on November 27, 2018 suggested that the stock is Equal-Weight.
Aldeyra Therapeutics Inc. (NASDAQ:ALDX) adds -$2.43 on Tuesday
The ALDX stock has tanked -39.04% year-to-date and is currently trading at $5.06, which is -60.44% below its 52-week high. The company shares lost -32.44% on the day and have risen nearly 17.40% off a low hit. As of 12/03/19, this stock has fallen -24.36% during the week and closed at $7.49 in the previous session. However, recent Aldeyra Therapeutics Inc. stock performance shows that ALDX shares are -13.80% down over the last month, and 9.52% up for the last three months.
Earnings per share (EPS) estimates for the current quarter are -$0.45, with the trailing 12-month share earnings at -$2.17. The ratio is expected to be down by -38.00% for the current year 2019 and -4.00% for next year. Over the next 5-year period, earnings per share will be 73.70%. But will the ALDX stock surprise in the current quarter results, where the -$0.69 actual EPS reported on 9/29/2019 surprised by -25.50% or was lower by -$0.14 from the estimated -$0.55.
Who owns shares in Aldeyra Therapeutics Inc. (ALDX)?
Let’s briefly focus on the share ownership of the Aldeyra Therapeutics Inc. (NASDAQ:ALDX) stock, where we find that 73.18% of shares are held by institutions. Perceptive Advisors Llc tops the list of institutional owners as it is holding 3.09 million shares or 11.04% of shares outstanding. 683 Capital Management LLC and Blackrock Inc. held 2.35 million and 1.59 million representing 8.41% and 5.67% respectively at the close of the last trading session. As of Sep 29, 2019, Adage Capital Partners GP L.L.C. accounted for 1.42 million shares at over 7.48 million. This represented 5.08% of shares outstanding. FMR, LLC held 1.34 million shares at over 7.07 million representing 4.80% of shares outstanding.
ALDX Insider Activity
On 3/26/2019, Director by the name Domain Associates Llc sold 96298.0 shares worth $963900.0 at the price of $10.01 per share. Filings also show that Brady Todd C bought a total of 18547.0 shares on 9/13/2019 valued at $109400.0. Since the last insider activity, the company’s share price has climbed 30.03%.